Posted by Michael Wonder on 28 Sep 2023
US FDA approves subcutaneous administration of Takeda's Entyvio (vedolizumab) for maintenance therapy in moderately to severely active ulcerative colitis
27 September 2023 - Entyvio is the only FDA approved ulcerative colitis biologic that offers the choice of intravenous or subcutaneous maintenance therapy.
Takeda today announced that the US FDA has approved a subcutaneous administration of Entyvio (vedolizumab) for maintenance therapy in adults with moderately to severely active ulcerative colitis after induction therapy with Entyvio intravenous.
